Background: In network meta-analysis (NMA), the magnitude of difference between treatment effects is typically ignored in the calculation of ranking metrics, such as probability best and surface under the cumulative ranking curve (SUCRAs). This leads to treatment rankings which may not reflect clinically meaningful differences. Minimally important differences (MIDs) represent the smallest value in a given outcome that is considered by patients or clinicians to represent a meaningful difference between treatments. There is a lack of literature on how MIDs can be incorporated into common NMA ranking metrics such as SUCRAs to give more clinically oriented treatment rankings.
Methods: Analogues to commonly available NMA ranking metrics that account for minimally important differences (MIDs) are provided. In particular, definitions are provided for MID-adjusted median ranks, MID-adjusted probability th best, MID-adjusted cumulative probability th best, and MID-adjusted SUCRA values. Since adjustment for MIDs allows for ties between treatments in a network, methods for handling ties in ranking are discussed, with it shown that the midpoint method for handling ties retains the property that the average value of all SUCRA values in a network is one half. Comparability of MID-adjusted P-scores and MID-adjusted SUCRA values is discussed, and a Bayesian software implementation of the MID-adjusted ranking metrics is provided.
Results: Two real-world applications of MID-adjusted ranking metrics are presented to illustrate their use. Specifically, NMAs are conducted based on published networks on treatments for diabetes and Parkinson's disease. To present the results, MIDs are selected from relevant literature to interpret MID-adjusted ranking metrics for these networks.
Conclusions: Failure to consider MIDs when ranking treatments can lead to ranking metrics which are not clinically relevant. Our proposed MID-adjusted Bayesian ranking metrics address this challenge. Further, we show that the use of the midpoint method for addressing ties ensures comparability between standard ranking metrics and MID-adjusted ranking metrics. The methods are easily applied in a Bayesian framework using the R package mid.nma.rank.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1186/s12874-025-02499-0 | DOI Listing |
Neuroradiology
March 2025
UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, CA, USA.
The universalizability of the metric percentage of signal recovery (PSR) derived from dynamic susceptibility contrast (DSC) perfusion MRI is limited by its dependency of acquisition parameters. In this technical assessment, we tested different reference tissues for PSR normalization and found the normal-appearing white matter (NAWM) to have the least inter-patient variability when using a fixed PSR-optimized protocol. A logarithmic normalization using NAWM improved the consistency of PSR values when a cohort of brain tumor patients was analyzed by synthetically changing acquisition parameters (while keeping the protocol uniform within the cohort).
View Article and Find Full Text PDFBMC Med Res Methodol
March 2025
Laboratory of Hygiene, Social & Preventive Medicine and Medical Statistics, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Background: In network meta-analysis (NMA), the magnitude of difference between treatment effects is typically ignored in the calculation of ranking metrics, such as probability best and surface under the cumulative ranking curve (SUCRAs). This leads to treatment rankings which may not reflect clinically meaningful differences. Minimally important differences (MIDs) represent the smallest value in a given outcome that is considered by patients or clinicians to represent a meaningful difference between treatments.
View Article and Find Full Text PDFbioRxiv
February 2025
Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, USA.
As the most common malignant pediatric brain cancer, medulloblastoma (MB) accounts for around 20% of all pediatric central nervous system (CNS) neoplasms. MB includes a complex array of distinct molecular subtypes, mainly including SHH, WNT, Group 3 and Group 4. Accurate identification of MB subtypes enables improved downstream risk stratification and tailored therapeutic treatment design.
View Article and Find Full Text PDFbioRxiv
February 2025
Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA.
The rapid expansion of readily accessible compounds over the past six years has transformed molecular docking, improving hit rates and affinities. While many millions of molecules may score well in a docking campaign, the results are rarely fully shared, hindering the benchmarking of machine learning and chemical space exploration methods that seek to explore the expanding chemical spaces. To address this gap, we develop a website providing access to recent large library campaigns, including poses, scores, and results for campaigns against 11 targets, with 6.
View Article and Find Full Text PDFACS Chem Biol
March 2025
Department of Chemistry and Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States.
Human ornithine transcarbamylase deficiency (OTCD) is the most common ureagenesis disorder in the world. OTCD is an X-linked genetic deficiency in which patients experience hyperammonemia to varying degrees depending on the severity of the genetic mutation. More than two-thirds of the known mutations are caused by single nucleotide substitutions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!